Exclusion Criteria (Core study):~1. Any neurological condition that may be contributing to cognitive impairment
above and beyond that caused by the subject's AD~2. History of transient ischemic attacks (TIA), stroke, or
seizures within 12 months of Screening~3. Any psychiatric diagnosis or symptoms, (e.g., hallucinations, major
depression, or delusions) that could interfere with study procedures in the subject~4. Geriatric Depression
Scale (GDS) score â‰¥8 at Screening~5. Contraindications to MRI scanning, including cardiac pacemaker/
defibrillator, ferromagnetic metal implants, e,g., in skull and cardiac devices other than those approved as
safe for use in MR scanners~6. Evidence of other clinically significant lesions that could indicate a dementia
diagnosis other than AD on brain MRI at Screening, or other significant pathological findings on brain MRI at
Screening~7. A prolonged QT/QTc interval (QTc greater than 450 ms) as demonstrated by a repeated
electrocardiogram (ECG)~8. Certain other specified medical conditions~9. Severe visual or hearing impairment
that would prevent the subject from performing psychometric tests accurately~Exclusion Criteria (Extension
Phase):~1. Subjects who discontinued from the study drug or from the Core Study for reasons other than the
following:~ 1. ARIA-E~ 2. ARIA-H (superficial siderosis, macrohemorrhage, or symptomatic microhemorrhage)~ 3.
Prohibited or restricted medications that were prohibited during Core Study conduct but are no longer
prohibited in the Extension Phase~ 4. Subjects who were APOE4 positive and receiving treatment with lecanemab
10 mg/kg biweekly~ 5. AE that was considered not related to study drug, and that was not severe or
life-threatening~2. Females of childbearing potential who do not agree to use a highly effective method of
contraception~3. Severe visual or hearing impairment that would prevent the subject from performing
psychometric tests accurately.
